RepliCel Presents Further Clinical Data and Corporate Update at its Annual General Meeting of Shareholders
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 06/11/12 -- (the "Company" or "RepliCel") (OTCBB: REPCF) presented significant new data from its Phase I/IIa first-in-man clinical trial at its Annual General Meeting ("AGM") of Shareholders held on Monday, June 11, 2012. To view a copy of the presentation, please
David Hall, RepliCel's President and CEO, stated, "As previously reported, a 6-month interim analysis of data from RepliCel's first-in-man clinical trial revealed that the RepliCel™ treatment is safe and effective. This news is significant, as it allows us to move forward with our Phase II dosing trial. RepliCel's team is working with European regulators to finalize protocols for the Phase IIb clinical trial application, expected to commence in late 2012. The Phase IIb clinical trial will be designed to optimize treatment regimen for hair growth. Several different treatment regimens will be tested, including different concentrations of cells and different treatment schedules, including single and repeat injections." Mr. Hall further stated, "The Company is also focused on optimizing the RepliCel™ procedure with the objectives of enhancing cell yield and isolation from scalp biopsies and improving cell replication yield and processing time."
Over the past six months, the Company has raised over USD$2.8 million through a series of private placements. These funds will be used for the continued advancement of the RepliCel™ technology.
About RepliCel Life Sciences Inc.
The Company has developed RepliCel™, a patented natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, initiates natural hair regeneration. The Company is currently conducting first-in-man clinical trials. Additional information on RepliCel is available at .
Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements, including that the Company will complete a Phase IIb clinical trial and that RepliCel™ has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements. These risks and uncertainties include: whether the Company can obtain regulatory approval for its planned Phase IIb clinical trial; that negative results may result from the Company's clinical trials; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital to carry out its planned activities; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2011, and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at and with the British Columbia Securities Commission on SEDAR at .
Contacts:
RepliCel Life Sciences Inc.
Tammey George
Director of Communications
604-248-8696
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.06.2012 - 17:58 Uhr
Sprache: Deutsch
News-ID 155189
Anzahl Zeichen: 0
contact information:
Town:
VANCOUVER, BRITISH COLUMBIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"RepliCel Presents Further Clinical Data and Corporate Update at its Annual General Meeting of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von
RepliCel Life Sciences Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
